Roche unit accused of stepping on D&I pledge with lawsuit

Roche unit Spark Therapeutics (STI) is pursuing a “misguided” lawsuit that contravenes its stated mission to combat systemic racism, according to gene therapy developer Bluebird Bio.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Amgen and Roche target Samsung’s Bioepis in patent suit

1 May 2019 Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.

Big Pharma

Amgen asks SCOTUS to reject Roche petition

14 April 2021 Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

Big Pharma

Novartis to sell Roche shares back for $20.7 billion

5 November 2021 Novartis yesterday, November 4, announced that it is selling its entire stake in Roche—equating to 53.3 million bearer shares—back to the Swiss healthcare company for the sum of $20.7 billion.

More on this story

Big Pharma

Amgen and Roche target Samsung’s Bioepis in patent suit

1 May 2019 Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.

Big Pharma

Amgen asks SCOTUS to reject Roche petition

14 April 2021 Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

Big Pharma

Novartis to sell Roche shares back for $20.7 billion

More on this story

Big Pharma

Amgen and Roche target Samsung’s Bioepis in patent suit

1 May 2019 Amgen and Roche have filed a joint patent infringement claim against Samsung’s biopharmaceutical company Bioepis.

Big Pharma

Amgen asks SCOTUS to reject Roche petition

14 April 2021 Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

Big Pharma

Novartis to sell Roche shares back for $20.7 billion